The closest thing to a public proxy for consumer digital mental health is Hims and Hers, and its first quarter of 2026 is a useful place to check what happened to the category thesis. The answer is not that telepsychiatry failed. It is that the company built to sell it stopped being a mental health company.

The quarter

Hims reported first-quarter 2026 revenue of $608.1 million, up about 4 percent year over year and short of the roughly $617 million analysts expected. The company swung to a net loss of $92.1 million, against a profit in the same quarter a year earlier, and posted a loss per share of $0.40 versus an expected small profit. Adjusted EBITDA fell to about $44 million from about $91 million. Gross margin compressed to 65 percent from 73 percent. The stock dropped more than 14 percent on the print. The subscriber base reached nearly 2.6 million, up 9 percent, and the company raised full-year guidance to a range of $2.8 to $3.0 billion.

A 4 percent revenue quarter with a swing to losses and an eight-point gross-margin compression is not a mental health story at all. It is a weight-loss story.

Where the growth and the pain came from

The margin compression and the loss both trace to a strategic pivot in the company’s United States weight-loss business, a shift from compounded GLP-1 medications toward branded ones supplied through partnerships with Novo Nordisk and Eli Lilly. Branded GLP-1s carry lower margins than the compounded products they replaced, and the transition brought inventory write-downs and other restructuring charges. The growth, meanwhile, came substantially from outside the core business: international revenue surged to about $78 million, nearly ten times the prior-year figure, helped by the company’s expansion abroad. The chief executive’s framing is explicit. The goal is to become the largest consumer health platform, not the largest mental health provider.

Where mental health actually sits

On the Hims platform, mental health is one specialty among several: weight management, sexual health, dermatology, hormone therapy, diagnostics, and mental health. The company reports market-share context across these specialties but does not break out mental health as a discrete revenue line, which is itself the tell. The offering is online psychiatry of a particular kind: an intake questionnaire that includes the standard PHQ-9 and GAD-7 depression and anxiety screens, access to a provider, generic prescriptions such as sertraline, and, separately, compounded anxiety and depression formulations that are not FDA-approved.

That is a competent cash-pay telepsychiatry product. It is not the center of the business, and the company’s own disclosures and its executives’ language make clear it is not meant to be. Mental health is a feature of the platform, retained because it brings in subscribers and rounds out the offering, not a category the company is organizing itself around.

The thesis that did not survive

The investment story for consumer digital mental health, in its 2020 to 2022 form, held that telehealth psychiatry was a standalone category large enough to build a company on, and that demand unlocked by the pandemic would make it durable. What actually happened is more specific and more instructive. The platform that won did not win with a better mental health product that displaced the incumbents. It absorbed mental health into a general consumer-health subscription whose marginal growth, and now its margin pressure, both come from weight loss. Telepsychiatry succeeded as a feature and disappeared as a category.

The contrast with the other branch of digital mental health sharpens the point. The companies that tried to make digital mental health a regulated medical category, building prescription digital therapeutics intended for payer reimbursement, have had a harder road, a subject the desk has covered separately in its work on the digital therapeutic benefit. The commercial winner took the opposite approach. It avoided the reimbursement question entirely by selling cash-pay subscriptions across many specialties, and it let weight loss, not mental health, carry the growth.

What to watch

The signal in the Hims quarter is the mix. A platform buying revenue growth in a low-margin category while a higher-margin, slower-growing specialty recedes is a platform whose identity has shifted, and the eight-point gross-margin move is the number that shows it. For anyone tracking digital mental health as an investable category rather than a clinical service, the takeaway is that the category’s bellwether is now reporting a weight-loss-and-international story, with mental health along for the ride.

That is not a failure of telepsychiatry. People are using these services, and the screens and prescriptions are real care for real patients. It is the end of a particular thesis: that consumer digital mental health would be a business unto itself. It became, instead, one line on a platform that needed several lines to work. The next few quarters at Hims will be about GLP-1 margins and overseas growth. Mental health will be in the footnotes, which is exactly where the company has decided it belongs.